TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00252564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg over 30 minutes on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg over 30 minutes on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
Study: NCT01539564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl Microspheres
Study: NCT01936662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA
Description: Patients randomized to the LMA group had their airways maintained with a LMA device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETT
Description: Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
Study: NCT01327976

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vBloc (Active Device)
Description: Active device will deliver vBloc Therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (Non-active Device)
Description: Functional non-active control device will deliver no vBloc Therapy
Study: NCT00414479

Intervention type: DRUG
Intervention: praziquantl, iron, ACT
Study: NCT02588911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Catheter-based ablation of the great saphenous vein
Study: NCT02772822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT400 plus CHOP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab plus CHOP
Study: NCT01957280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patritumab
Study: NCT00796913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop medication
Description: Stop medication Stop medication + se supplement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stop medication
Description: Stop medication Stop medication + se supplement
Study: NCT02663661

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Metabolic Challenge Admission
Description: A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Metabolic Challenge Admission
Description: A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Metabolic Challenge Admission
Description: A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.

Intervention type: OTHER
Group type: OTHER
Intervention: CGM home test
Description: A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.

Intervention type: OTHER
Group type: OTHER
Intervention: CGM home test
Description: A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.

Intervention type: OTHER
Group type: OTHER
Intervention: CGM home test
Description: A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
Study: NCT04605835

Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASONIC VISUALIZATION OF OBSTRUCTIVE UROPATHIES IN CHILDREN.
Description: The purpose of this study was to develop proposals and recommendations for improving the safety of urological examination of children with obstructive uropathy by using Doppler ultrasound. Based on the results of a comprehensive urological examination of 665 children with congenital ureteral obstruction, a program for scoring the results of ultrasound examination has been developed, which allows using the safest and most informative methods to reliably determine the functional state of the renal parenchyma and the degree of urodynamic disorders in children with obstructive uropathy.
Study: NCT01531816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation intervention
Description: 1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention.
Study: NCT02694536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m\^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
Study: NCT02396888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Half of the wound surface was treated daily with 10 units of intermediate insulin.
Study: NCT03787004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-6970
Description: Oral dose CNTX-6970

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose placebo
Study: NCT04503551

Intervention type: DRUG
Group type: OTHER
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Ranibizumab 0.5 mg Injection
Description: Will be administered as per the schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab 0.5 mg Injection
Description: Will be administered as per the schedule described in individual arm.
Study: NCT03867500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of 0.9% Sodium chloride (NaCl)
Study: NCT01823796

Intervention type: OTHER
Intervention: Fibromyalgia women group
Description: Assessment of this group at baseline in order to be compared with a control group.

Intervention type: OTHER
Intervention: Healthy women
Description: These women are assessed in order to be compared with fibromyalgia women group.
Study: NCT04050007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive initiation of fluid removal
Description: Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Curative initiation of fluid removal
Description: The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines
Study: NCT02039271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
Study: NCT00312780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL784
Description: XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XL784
Description: XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
Study: NCT00849303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait-oriented rehabilitation
Description: Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait-oriented rehabilitation
Description: Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
Study: NCT01025778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine for remission induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide for remission induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for remission induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine in conditioning before transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa in conditioning before transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melfalan in conditioning before transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical transplantation of T-cell depleted graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Study: NCT01971879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff.
Study: NCT01204281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation mode (PAV+ vs. ACV)
Description: Compare two ventilatory modes in the acute phase of illness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation mode (PAV+ vs. ACV)
Description: Compare two ventilatory modes in the acute phase of illness
Study: NCT03178890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OHMG
Description: Device will be implanted in all enrolled patients.
Study: NCT04355689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-001
Description: oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT02615496

Intervention type: BEHAVIORAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.

Intervention type: BEHAVIORAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD.
Study: NCT02917538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Both groups will receive radiofrequency ablation treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Both groups will receive radiofrequency ablation treatment
Study: NCT02396888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the wound surface was treated daily with 0.1 cc of normal saline.
Study: NCT00004163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT03876808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair Hugger™ Temperature Management Unit Model 750
Description: Forced-air temperature management unit used for preoperative and intraoperative participant warming

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ Bair Paws™ Flex Gown
Description: Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
Study: NCT04009135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet delivered cognitive behavioural therapy (iCBT)
Description: The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online delivered acceptance and commitment therapy (iACT)
Description: The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind \& acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AC)
Description: 1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
Study: NCT03958604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurostimulation
Description: Spinal cord stimulation with burst modality for discogenic low back pain
Study: NCT00100750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT06472570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy boost
Description: A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy
Study: NCT02015832

Intervention type: DEVICE
Intervention: Coronary stent

Intervention type: RADIATION
Intervention: Multi Slice Computed Tomography
Description: A coronary non-invasive Multi Slice Computed Tomography will be performed in patients

Intervention type: DEVICE
Intervention: instantaneous wave-free ratio
Description: Pressure-derived, adenosine-free index on physiological assessment of stenosis severity

Intervention type: DEVICE
Intervention: Fractional flow reserve
Description: Pressure-derived index on physiological assessment of stenosis severity

Intervention type: DEVICE
Intervention: Intravascular Ultrasound
Description: Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
Study: NCT00550147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oros Methylphenidate
Description: Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule.
Study: NCT03209115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination of calcium hydroxide and chlorhexidine
Description: placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
Study: NCT01214980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST Therapy
Description: Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care provided per site-specific protocol
Study: NCT01074827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training and treadmill training
Description: Eight weeks of intensive strength training or treadmill training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training and treadmill training
Description: Eight weeks of intensive strength training or treadmill training
Study: NCT00402350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo, same number of doses as active comparator in that arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg
Description: Inhaled Staccato Fentanyl, 25 mcg x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl 25 mcg
Description: Intravenous Fentanyl 25 mcg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 2
Description: Inhaled Staccato Fentanyl, 25 mcg x 2 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 4
Description: Inhaled Staccato Fentanyl, 25 mcg x 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 6
Description: Inhaled Staccato Fentanyl, 25 mcg x 6 doses
Study: NCT04090398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT02545530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal clonidine
Description: 2.5mg/patch per week
Study: NCT02439411

Intervention type: DRUG
Intervention: Trametinib
Study: NCT00402350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Fentanyl 25 mcg x 12
Description: Inhaled Staccato Fentanyl, 25 mcg x 12 doses